Omeros (NASDAQ:OMER) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

Shares of Omeros Co. (NASDAQ:OMER) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.97 and traded as high as $4.36. Omeros shares last traded at $4.26, with a volume of 189,131 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Friday, August 16th.

Omeros Price Performance

The business’s 50 day simple moving average is $3.99 and its 200 day simple moving average is $3.97. The stock has a market cap of $244.54 million, a P/E ratio of -1.83 and a beta of 1.48.

Omeros (NASDAQ:OMER) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter. Research analysts predict that Omeros Co. will post -2.9 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Omeros by 2.6% in the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after buying an additional 81,348 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Omeros in the 1st quarter worth approximately $538,000. Rhumbline Advisers grew its position in Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 6,435 shares during the last quarter. Finally, Cypress Capital Group increased its holdings in Omeros by 40.0% during the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.